Suggested remit: To appraise the clinical and cost effectiveness of dapagliflozin within its marketing authorisation for treating chronic heart failure with preserved ejection fraction.
 
Status In progress
Technology type Medicine
Decision Selected
Reason for decision Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources
Process STA 2018
ID number 1648

Project Team

Project lead Emily Richards

Email enquiries

Timeline

Key events during the development of the guidance:

Date Update
26 January 2022 - 23 February 2022 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators
26 January 2022 In progress

For further information on our processes and methods, please see our CHTE processes and methods manual